Modified streptococcal polysaccharides and uses thereof

Details Modified streptococcal polysaccharides and uses thereof Modified streptococcal polysaccharides and uses thereof

2005-11-01

2010-12-28

Devi, S. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S234100, C424S197110, C424S203100, C424S184100, C424S194100, C424S831000, C514S023000, C536S123100

Reexamination Certificate

active

07858101

ABSTRACT:
Modified streptococcal polysaccharides and methods of using the modified polysaccharides are provided herein.

REFERENCES:
patent: 4207414 (1980-06-01), Kasper
patent: 4284537 (1981-08-01), Beachey
patent: 4324887 (1982-04-01), Kasper
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4356263 (1982-10-01), Kasper
patent: 4367221 (1983-01-01), Kasper
patent: 4367222 (1983-01-01), Kasper
patent: 4367223 (1983-01-01), Kasper
patent: 4425330 (1984-01-01), Norcross et al.
patent: 4438261 (1984-03-01), Barnett
patent: 4619828 (1986-10-01), Gordon
patent: 4757134 (1988-07-01), Blake et al.
patent: 4789735 (1988-12-01), Frank et al.
patent: 4902506 (1990-02-01), Anderson et al.
patent: 5302386 (1994-04-01), Kasper et al.
patent: 5472696 (1995-12-01), Boyle et al.
patent: 5648241 (1997-07-01), Michel et al.
patent: 5795580 (1998-08-01), Jennings et al.
patent: 5820860 (1998-10-01), Michel et al.
patent: 5843444 (1998-12-01), Michel et al.
patent: 5843461 (1998-12-01), Jennings et al.
patent: 5847081 (1998-12-01), Michel et al.
patent: 5858362 (1999-01-01), Michel et al.
patent: 5908629 (1999-06-01), Michel et al.
patent: 5968521 (1999-10-01), Michel et al.
patent: 5993825 (1999-11-01), Jennings et al.
patent: 6355255 (2002-03-01), Cleary et al.
patent: 2004/0071729 (2004-04-01), Adderson et al.
patent: 94/06467 (1994-03-01), None
patent: 2004/011027 (2004-02-01), None
Gottormsen et al. PNAS 105: 5903-5908, 2008.
Poland GA. Vaccine 17: 1674-1679, 1999.
Kasper et al., “Immune Response to Type III Group B Streptococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine”J. Clin. Invest. 98:2308-2314 (1996).
Kong et al., “Molecular Profiles of Group B Streptococcal Surface Protein Antigen Genes: Relationship to Molecular Serotypes”J. Clin. Microbiol. 40:620-626 (2002).
Lachenauer et al., “Mosaicism in the alpha-like protein genes of group B streptococci”Proc. Natl. Acad. Sci. USA97:9630-9635 (2000).
Larsson et al., “Experimental Vaccination against Group B Streptococcus, an Encapsulated Bacterium, with Highly Purified Preparations of Cell Surface Proteins Rib and α”Infect. Immun. 64(9):3518-3523 (1996).
Michel et al., “Cloned Alpha and Beta C-Protein Antigens of Group B Streptococci Elicit Protective Immunity”Infect. Immun. 59(6):2023-2028 (1991).
Michel et al., “Large, identical, tandem repeating units in the C protein alpha antigen gene,bca, of group B streptococci”Proc. Natl. Acad. Sci. USA89: 10060-10064 (1992).
Rench et al., “Neonatal sepsis caused by a new group B streptococcal serotype”J. Pediatr. 122(4):638-640 (1993).
Rodewald et al., “Neonatal Mouse Model of Group B Streptococcal Infection”J. Infect. Dis. 166(3):635-639 (1992).
Schwartz et al., “Proteins Containing Reductively Aminated Disaccharides”Arch. Biochem. Biophys. 181:542-549 (1977).
Spellerberg et al., “Lmb, a Protein with Similarities to the LraI.adhesion Family, Mediates Attachment ofStreptococcus agalactiaeto Human Laminin”Infect. Immun. 67(2):871-878 (1999).
Tettelin et al., “Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype VStreptococcus agalactiae” Proc. Natl. Acad. Sci. USA99(19):12391-12396 (2002).
Wang et al., “Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling”Vaccine21(11-12):1112-1117 (2003).
Wästfelt et al., “Identification of a Family of Streptococcal Surface Proteins with Extremely Repetitive Structure”J. Biol. Chem. 271(31):18892-18897 (1996).
Wessels et al., “Immunogenicity and protective activity in animals of a group BStreptococcustype V polysaccharide-tetanus toxoid conjugate vaccines”J. Infect. Dis.171:879-884 (1995).
Wessels et al., “Immunogenicity in Animals of a Polysaccharide-Protein Conjugate Vaccine against Type III Group BStreptococcus” J. Clin. Invest. 86:1428-1433 (1990).
Wessels et al., “Structural Determination and Immunochemical Characterization of the Type V Group BStreptococcusCapsular Polysaccharide”J. Biol Chem. 266(11):6714-6719 (1991).
Zaleznik et al., “Invasive Disease Due to Group B Streptococcus in Pregnant Women and Neonates from Diverse Population Groups”Clin. Infect Dis. 30(2):276-281 (2000).
Palazzi et al., “Use of Type V Group B Streptococcal Conjugate Vaccine in Adults 65-85 Years Old”J. Infect. Dis. 190:558-564 (2004).
Adderson et al., “Subtractive Hybridization Identifies a Novel Predicted Protein Mediating Epithelial Cell Invasion by Virulent Serotype III Group BStreptococcus agalactiae” Infect. Immun. 71(12):6857-6863 (2003).
Anthony et al., “The Emergence of Group B Streptococci in Infections of the Newborn Infant”Annu. Rev. Med. 28:355-369 (1977).
Baker et al., “Immune Response of Healthy Women to 2 Different Group B Streptococcal Type V Capsular Polysaccharide-Protein Conjugate Vaccines”J. Infect. Dis. 189:1103-1112 (2004).
Baker et al., “Safety and Immunogenicity of Capsular Polysaccharide-Tetanus Toxoid Conjugate Vaccines for Group B Streptococcal Types Ia and Ib”J. Infect. Dis. 179:142-150 (1999).
Baker et al., “Use of Capsular Polysaccharide—Tetanus Toxoid Conjugate Vaccine for Type II Group BStreptococcusin Healthy Women”J. Infect. Dis. 182:1129-1138 (2000).
Baker, “Group B Streptococcal Infections”Adv. Intern. Med. 25:475-501 (1980).
Blumberg et al., “Invasive group B streptococcal disease: The emergence of serotype V”J. Infect. Dis. 173:365-373 (1996).
Deng et al., “Characterization of the Linkage between the Type III Capsular Polysaccharide and the Bacterial Cell Wall of Group BStreptococcus” J. Biol. Chem. 275(11):7497-7504 (2000).
Dillion et al., “Group B streptococcal carriage and disease: A 6 year prospective study”J. Pediatr. 110(1):31-36 (1987).
Elliott et al., “Sudden increase in isolation of group B streptococci, serotype V, is not due to emergence of a new pulsed-field gel electrophoresis type”J. Clin. Microbiol. 36:2115-2116 (1998).
Farley et al., “Group B streptococcal disease in nonpregnant adults”Clin. Infect. Dis. 33:556-561 (2001).
Ferrieri, “Surface-Localized Protein Antigens of Group B Streptococci”Rev. Infect. Dis. 10(Suppl. 2):S363-S366 (1988).
Greenberg et al., “Group B streptococcus serotype V”J. Pediatr. 123(3):494-495 (1993).
Harrison et al., “Serotype distribution of invasive group B streptococcal isolates in Maryland: Implications for vaccine formulation”J. Infect. Dis. 177:998-1002 (1998).
Heden et al., “Molecular characterization of IgA receptor from group B streptococci: sequence of the gene, identification of a proline-rich region with unique structure and isolation of N-terminal fragments with IgA-binding capacity”Eur. J. Immunol. 21(6):1481-1490 (1991).
Hervás et al., “Neonatal sepsis caused by a new group B streptococcal serotype (type V)”J. Pediatr. 123(5):839 (1993).
Jelinkova et al., “Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V”J. Clin. Microbiol. 21:361-362 (1985).
Baker et al., “Group B streptococcal conjugate vaccines,” Archives of Disease in Childhood 88(5):375-378 (2003).
Molinari et al., “Effects of some capsular components on pathogenicity of type IV and provisional type V group B streptococci,” FEMS Microbiology Letters 41(1):69-72 (1987).

Affiliated with

Also associated with

Rating

Modified streptococcal polysaccharides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified streptococcal polysaccharides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified streptococcal polysaccharides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4201443